GSK Partners With Santaris On RNA Antagonists For Viral Disease

$700 million deal gives GlaxoSmithKline options on up to four different viral disease programs; deal marks Santaris’ expansion into virology, chief exec McCullah tells “The Pink Sheet” DAILY.